ライフサイエンスコーパス: were included

1 oscopic and ancillary findings indicative of IFD (n = 116), were included.

2 itted with BAPT from January 1, 2006, to December 31, 2013, were included.

3 MR imaging for screening or staging from 2010 through 2014 were included.

4 Of 374 studies identified by our search, 30 were included in our study, only eight of which included dete

5 roup and 180 in pest management education alone group), 334 were included in the primary analysis.

6 ies, 4994 patients underwent randomization and 4919 (98.5%) were included in the primary analysis.

7 Among 480 randomized participants, 465 (97%) were included in the modified intention-to-treat analysis (me

8 (n = 216) and 300 randomly selected individuals without AN were included in the analysis.

9 leven patients (11 eyes) had undergone vitreous surgery and were included in the study.

10 lective resections for a T1-3N0-2M0 stage colorectal cancer were included between 2010 and 2012 in 29 Dutch hospitals.

11 181 (99%) of 183 children were included in the modified intention-to-treat analysis.

12 available data on the date of their initial cholecystectomy were included.

13 Markers on one chromosome were included simultaneously in a multilocus model and least

14 d in the Natural History Project of the Dystonia Coalition, were included in the analysis.

15 mplete risk factor profiles, and were free of clinical CVD, were included in this study.

16 ctional kidney but failed pancreas allografts after 90 days were included.

17 All patients who received at least one dose of study drug were included in all analyses.

18 tients in the PENFS group and 47 patients in the sham group were included in the primary analysis.

19 cile, glomerular filtration rate, and total bilirubin level were included in a simplified model and incorporated into the

20 B1(+) field and variable flip angle (FA) mapping were included in the dynamic contrast-enhanced breast MR imag

21 apse while receiving treatment with alternative medications were included in this trial.

22 214 patients with thrombotic microangiopathy were included in the derivation cohort.

23 /ml collected a median of 5 months apart (IQR: 2-11 months) were included.

24 n the standard repair arm assigned to all treatment options were included in the standard repair group of both trials.

25 , seven trials with 363 dental implants in 262 participants were included in the analysis.

26 nal editors (n = 9), and regulators (n = 2) (3 participants were included in 2 groups each), culminating in a consensus m

27 Twenty-one studies (13982 participants) were included.

28 One hundred and eighteen eyes of 118 patients were included in the study.

29 60 patients were included and 50 completed the study (56 +/- 8 years old;

30 enty-three randomized controlled trials with 2,751 patients were included.

31 Hershey Medical Center, 95 patients were included in this systematic review.

32 All consenting patients were included, with no exclusion criteria.

33 ight-handed healthy volunteers and 35 mixed-handed patients were included.

34 least one dose of study drug during the maintenance period were included in the primary efficacy and safety analyses.

35 undergoing PVI from the Swedish Catheter Ablation Register were included, with information about exposure to warfarin in

36 eoadjuvant chemoradiotherapy followed by surgical resection were included.

37 ervention (injection of dye), regardless of mapping result, were included as part of the assessment of mapping and in the

38 patients with a PDA stent and 251 patients with a BT shunt were included.

39 and 15 control participants from a prospective cohort study were included, which was approved by the local ethics board a

40 ,256 adult participants (women: 51.0%) from Northern Sweden were included (7121 deaths; mean follow-up: 13.7 y).

41 Two hospitals in Tanga Region, Tanzania were included in the study, 1 randomly assigned to receive th

42 40 810 adult travelers were included; providers considered 6612 (16%) to be eligible

43 amount of study drug, with treatment assignment as treated, were included in the safety analysis.

44 nce and the acquisition of drug resistance during treatment were included.

45 All patients who received treatment were included in an intent-to-treat analysis of the response

46 Overall, all 1059 patients from the Mainsail trial were included (mean [SD] age, 68.7 [7.89] years).

47 lus evofosfamide and 323 to doxorubicin alone), all of whom were included in the intention-to-treat analysis.

48 et before 18 years of age and duration of less than 4 years were included in this study.

49 dred ninety-seven eyes with a median follow-up of 2.6 years were included.

50 trials (n = 40058; range, 142-16608; mean age, 53-79 years) were included.